• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Dapagliflozin Effective in T2D with HFrEF Regardless of Type of Background T2D Therapy

Video
Conference|ADA

VIDEO: Kieran Docherty, MBChB, discusses results of the DAPA-HF analysis on the impact of background T2D therapy on clinical outcomes in patients with T2D and HFrEF.


In the DAPA-HF trial, the SGLT-2 inhibitor dapagliflozin improved clinical outcomes in patients wtih heart failure with reduced ejection fraction, with or without type 2 diabetes (T2D). Kieran Docherty, MBChB, discusses results of an important DAPA-HF subanalysis that found dapagliflozin benefits are not affected by background T2D therapy or the type of therapy. Results were presented at the recent 2020 American Diabetes Association Scientific Sessions.

Related Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Elevated Lp(a) Level Raises ASCVD Risk Regardless of Age, Sex, Race/Ethnicity: Daily Dose / image credit: ©New Africa/AdobeStock

Elevated Lp(a) Level Raises ASCVD Risk Regardless of Age, Sex, Race/Ethnicity: Daily Dose

April 24th 2024
Article

Your daily dose of the clinical news you may have missed.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort / image credit ASCVD: ©Rasi/stock.adobe.com

Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort

April 16th 2024
Article

Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D / image Mikhail Kosiborod, MD St Luke's Mid America Heart institute

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D

April 8th 2024
Article

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age / image credit weightloss: ©CLIPAREA/shutterstock.com

Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests

April 5th 2024
Article

In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.

© 2024 MJH Life Sciences

All rights reserved.